Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
2,981,329

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.

Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $80.76 in the latest trading session, marking a +0.2% move from the prior day.

Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

Gilead & Galapagos Announce Positive Data on Arthritis Drug

Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan

AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $79.64, moving -0.15% from the previous trading session.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $80.65 in the latest trading session, marking a -0.85% move from the prior day.

Roche Receives EC Approval for Label Expansion of Hemlibra

Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.

Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $78.08, marking a +0.64% move from the previous day.

Should Value Investors Consider Abbvie (ABBV) Stock Now?

Let's see if Abbvie (ABBV) stock is a good choice for value-oriented investors right now from multiple angles.

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC

Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.

Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy

The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy

AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.

Mark Vickery headshot

Top Research Reports for Intel, AbbVie & United Technologies

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), AbbVie (ABBV) and United Technologies (UTX).

Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices

Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.

Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat

Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie